SCHEMBL4155878

SCHEMBL4155878

O=C1NC(=O)C2(N1)C(=O)N(Cc1cnc(Cl)s1)c1ccccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.38
ALDH1A1 P00352 3/20 0.38
ITGA4 P13612 1/20 0.38
SCN9A Q15858 7/20 0.38
AKR1B1 P15121 2/20 0.37
AKR1A1 P14550 1/20 0.37
RECQL P46063 1/20 0.36
KMT2A Q03164 1/20 0.36
ALPL P05186 1/20 0.36
MAPT P10636 2/20 0.34
CACNA1F O60840 1/20 0.34
CYP2C9 P11712 1/20 0.34
HTR2A P28223 1/20 0.34
HRH1 P35367 1/20 0.34
SCN1A P35498 1/20 0.34
SCN4A P35499 1/20 0.34
BLM P54132 1/20 0.34
PMP22 Q01453 1/20 0.34
CACNA1D Q01668 1/20 0.34
KCNH2 Q12809 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4171615 0.87 AKR1B1 (0.44) AKR1B1AKR1A1MAPTTP53
SCHEMBL4166796 0.85 AKR1B1 (0.43) AKR1B1AKR1A1
SCHEMBL4161684 0.85 L3MBTL1 (0.39) LMNAALDH1A1AKR1B1AKR1A1MAPT
SCHEMBL4172070 0.80 SCN9A (0.44) ALDH1A1ITGA4SCN9AALPLMAPT
SCHEMBL4254336 0.80 ALDH1A1 (0.51) ALDH1A1ITGA4SCN9AALPLMAPT
SCHEMBL4164812 0.77 AKR1B1 (0.35) LMNAALDH1A1AKR1B1AKR1A1KCNH2
SCHEMBL10802626 0.75 APAF1 (0.48) ALDH1A1ITGA4SCN9AAKR1B1AKR1A1
SCHEMBL10954920 0.74 ALPL (0.41) ALDH1A1ITGA4SCN9AAKR1B1AKR1A1
SCHEMBL4259950 0.73 TP53 (0.50) LMNAAKR1B1AKR1A1MAPTTP53
SCHEMBL4167707 0.73 RAB9A (0.49) LMNAALDH1A1SCN9AAKR1B1AKR1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090076049-A1 Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 ASTRAZENECA AB (SE) 2009-03-19 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076049-A1 Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 TRPV1, TRPV5, TRPV2 LMNA 3199/4885ALDH1A1 550/4885ITGA4 1856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.